A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19.
As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.
COPCOV has recruited participants from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, Thailand, Niger and the UK. Preliminary study results are expected early Q2 2022.